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Modern ischaemic stroke management involves intravenous thrombolysis followed by 
mechanical thrombectomy, which allows markedly higher rates of recanalization and 
penumbral salvage than thrombolysis alone. However, <50% of treated patients 
eventually enjoy independent life. It is therefore important to identify complementary 
therapeutic targets. In rodent models, the salvaged penumbra is consistently affected 
by selective neuronal loss, which may hinder recovery by interfering with plastic 
processes, as well as by microglial activation, which may exacerbate neuronal death. 
However, whether the salvaged penumbra in man is similarly affected is still unclear. 
Here we determined whether these two processes affect the non-infarcted penumbra in 
man and, if so, whether they are inter-related. 
We prospectively recruited patients with i) acute middle-cerebral artery stroke; ii) 
penumbra present on CT perfusion obtained <4.5hrs of stroke onset; and iii) early 
neurological recovery as a marker of penumbral salvage. Positron-emission 






C-PK11195, as well as magnetic 
resonance imaging to map the final infarct, were obtained at pre-defined follow-up 
times. The presence of selective neuronal loss and microglial activation was 
determined voxel-wise within the magnetic-resonance imaging normal-appearing 
ipsilateral non-infarcted zone and surviving penumbra masks, and their inter-
relationship was assessed both across and within patients. Dilated infarct contours 
were consistently excluded to control for partial volume effects. 
Across the 16 recruited patients, there was reduced 
11
C-Flumazenil and increased 
11
C-
PK11195 binding in the whole ipsilateral non-infarcted zone (p=0.04 and 0.02, 
respectively). Within the non-infarcted penumbra, 
11
C-Flumazenil was also reduced (p 
= 0.001), without clear increase in 
11





C-PK11195 in either compartment. 
This mechanistic study provides direct evidence for the presence of both neuronal loss 
and microglial activation in the ipsilateral non-infarcted zone. Further, we 
demonstrate the presence of neuronal loss affecting the surviving penumbra, with no 
or only mild microglial activation, and no significant relationship between these two 
processes. Thus, microglial activation may not contribute to penumbral neuronal loss 
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in man, and its presence in the ipsilateral hemisphere may merely reflect secondary 
remote degeneration. Selective neuronal loss in the surviving penumbra may represent 
a novel therapeutic target as an adjunct to penumbral salvage to further improve 
functional outcome. However, microglial activation may not stand as the primary 
therapeutic approach. Protecting the penumbra by e.g. improving perfusion and 
oxygenation in conjunction with thrombectomy may be a better approach. 
11
C-
Flumazenil PET would be useful to monitor the effects of such therapies.    
 




C-Flumazenil, acute stroke, recovery, cerebral 
ischemia, imaging, cerebral infarction, cerebral blood flow
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The ischaemic penumbra represents the main target for acute stroke therapy 
(Muir et al., 2006), and preventing it from progressing to infarction enhances 
neurological recovery (Furlan et al., 1996, Heiss et al., 1998). Reperfusion therapies, 
namely intravenous thrombolysis and mechanical thrombectomy, are now licensed to 
salvage the penumbra, which has revolutionized stroke management. In spite of these 
breakthroughs, however, functional outcome remains poor (i.e., lost independence) in 
the majority of treated patients, even despite the >80% recanalization rate afforded by 
thrombectomy (Emberson et al., 2014, Goyal et al., 2016). There is therefore an 
urgent need to identify novel therapeutic targets so as to improve functional recovery 
in successfully recanalized stroke patients (Fisher and Saver, 2015).  
In animal models the salvaged penumbra is consistently affected by selective 
neuronal loss (SNL) and resident microglia activation (MA)  (for review see (Baron et 
al., 2014)), and even isolated SNL at least transiently impacts sensorimotor 
performance (Sicard et al., 2006, Balkaya et al., 2013, Ejaz et al., 2015). Thus, SNL 
may hinder recovery by restricting neuronal plasticity in peri-infarct tissue, an area 
considered critical for recovery of lost functions (Cao et al., 1999, Cramer et al., 
2000, Calautti and Baron, 2003, Jaillard et al., 2005, Nudo, 2006). Accordingly, SNL 
may represent a novel therapeutic target for stroke. However, as it may exacerbate 
SNL via release of neurotoxic cytokines, MA might in fact represent the prime 
therapeutic target (Kaushal and Schlichter, 2008, Kriz and Lalancette-Hebert, 2009, 
Hu et al., 2012, Baron et al., 2014). This notion is supported by the finding in rodents 
of significant correlations between SNL and MA in the surviving penumbra (Hughes 
et al., 2010, Hughes et al., 2012). However, causality could just as well go in reverse 
given that MA is initially triggered by neuronal death (Schwartz, 2003, Kriz and 
Lalancette-Hebert, 2009). Alternatively, therefore, SNL could result from other 
mechanisms, such as delayed ischemic and/or reperfusion-related early neuronal 
death.  
At this point, however, the key issue with respect to clinical relevance is 
whether the surviving penumbra is also affected by SNL and MA in man, and if so, 
whether these two processes are correlated, which would point to MA as primary 
target. To address these issues, and eventually identify target populations for drug 
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trials, sensitive and selective imaging markers are required. Owing to the normality of 
conventional structural MRI in areas affected by SNL and MA in rodents (Li et al., 
1999, Sicard et al., 2006, Sicard et al., 2006, Wegener et al., 2006, Ejaz et al., 2013, 
Ejaz et al., 2015), radiolabeled tracers have been employed so far. Prominent among 
these are the positron emission tomography (PET) ligands 
11
C-Flumazenil (FMZ) and 
11
C-[R]-PK11195 (PK), respectively, both recently validated in rodent models as 
selective in vivo markers against post-mortem immunohistochemistry (Hughes et al., 
2012, Ejaz et al., 2013), confirming earlier in vitro studies showing co-localization of 
3
H-labelled PK and FMZ with activated microglia and SNL, respectively (Myers et 
al., 1991, Stephenson et al., 1995, Katchanov et al., 2003).  
Few clinical stroke studies have so far investigated these issues. Although an 
FMZ-PET study documented the presence of SNL in the non-infarcted MCA territory, 
it did not directly assess the surviving penumbra per se (Guadagno et al., 2008). Two 
other studies using 
123
I-Iomazenil (IMZ) single-photon emission tomography 
(SPECT) suggested the presence of SNL in the NIP (Nakagawara et al., 1997, Saur et 
al., 2006), but have limitations. The tracer IMZ is suboptimal due to very slow tissue 
kinetics making its uptake and subsequent binding dependent on perfusion (Videbaek 
et al., 1993, Videbaek et al., 1995), and furthermore in one study IMZ brain uptake 
was measured at an early post-injection timepoint (Saur et al., 2006), likely 
exaggerating this perfusion dependence. The poor spatial resolution of SPECT may 
cause the low IMZ uptake present in infarcted areas to contaminate peri-infarct areas, 
in turn overestimating SNL. Also, in one study (Saur et al., 2006), SPECT was 
performed 5-15 days post-stroke, when blood-brain barrier disruption is at its peak, 
while in the other the IMZ images were not coregistered with follow-up structural 
images (Nakagawara et al., 1997), preventing direct assessment of IMZ uptake in the 
surviving penumbra. A recent small-scale (n=7 patients) FMZ-PET study also from 
our group that assessed FMZ binding in relation to fMRI activation clusters reported a 
significant FMZ binding reduction in the non-activated part, but not the activated part, 
of the surviving penumbra (Carrera et al., 2013). Finally, a recent study using 
sophisticated cortex flattening methodology found reduced FMZ binding in the 
immediate peri-infarct area (Funck et al., 2017), but the relevance of this finding to 
the penumbra is unclear as acute-stage perfusion mapping was not part of this study. 
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Overall, therefore, although there is strong evidence of SNL in the non-infarcted 
MCA territory, whether it affects the surviving penumbra per se remains unsettled.  
Even fewer clinical studies have thus far assessed MA in non-infarcted tissue 
following MCA stroke, and none specifically the surviving penumbra. Two studies 
using PK-PET documented inflammation along the degenerating cortico-spinal tract 
(Radlinska et al., 2009, Thiel et al., 2010), and another (Pappata et al., 2000) in the 
ipsilateral thalamus, which the authors attributed to Wallerian and/or retrograde 
thalamo-cortical degeneration as readily observed in rodents (Dubois et al., 1988, 
Tamura et al., 1991, Rupalla et al., 1998, Arlicot et al., 2010, Walberer et al., 2014). 
In a study of six patients in whom PK-PET was performed 3-14 days post-stroke  
(Gerhard et al., 2005), MA was found in the non-infarcted ipsilateral hemisphere in 
four. However, as no measures were taken to control for the smearing of high within-
infarct PK uptake onto neighbouring areas, the validity of these findings is uncertain. 
Like in the above-mentioned studies, these authors also documented MA in connected 
areas of the ipsilateral hemisphere and thalamus and pons bilaterally, again attributing 
it to remote degeneration. In a small-scale study from our group where immediate 
peri-infarct areas were excluded from the analysis by applying infarct mask dilatation 
(Price et al., 2006), MA was found in the non-infarcted affected MCA territory in 
three patients. Taken together, there is preliminary evidence for the presence of MA in 
the non-infarcted MCA territory, however no study so far has assessed MA within the 
surviving penumbra per se.  
We therefore designed the present mechanistic study to address two main 
unanswered questions: i) is the non-infarcted penumbra affected by SNL and MA in 
man? ; and ii) does a quantitative correlation exist between these two processes? 
Based on the above evidence, we predicted the answer to both questions would be 
positive.   
To test these hypotheses, we prospectively enrolled a sizeable sample of acute 
MCA stroke patients with documented penumbra on admission CT perfusion (CTp) as 
well as early neurological improvement (ENI) as a marker of penumbral salvage, to 
undergo both PK and FMZ PET in the subacute/early chronic stage, and follow-up 
MRI to map the final infarct.   
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Material and Methods 
 
Patients 
We prospectively recruited adult subjects i) admitted within 6hrs of onset (or 
last-time-seen-well) of first-ever MCA stroke; ii) with admission NIHSS ≥2 (or 
isolated aphasia); iii) in whom admission CT perfusion (CTp) documented the 
presence of penumbra; and iv) who experienced ENI, defined as a gain in National 
Institute of Health Stroke Scale (NIHSS) score ≥8 within the first 24 hours or 
NIHSS≤2 at 24 hours (Saver, 2011), suggesting penumbral salvage. Eligible 
candidates were approached for consentment only after routine 24hrs NIHSS 
assessment and post-processing of the admission CTp data had provided evidence of 
ENI and penumbra, respectively. Assessment of recanalization, which is not part of 
routine stroke management, did not belong in the study’s imaging protocol. Exclusion 
criteria are listed in Supplemental Material.  
 
Clinical assessment  
Standard clinical data (age, gender, baseline observations, past medical 
history, vascular risk factors, drug and alcohol history, medications on admission and 
discharge, acute interventions for stroke administered and cause of stroke) were 
recorded for each recruited patient. Clinical course was determined by serial NIHSS 
measurements obtained on admission, at 24hrs and at each follow-up PET visit.  
 
Age-matched healthy controls 
To obtain normative values, stroke-age healthy volunteers were recruited and 
underwent either the FMZ or the PK scan (12 and 10 subjects, of gender (F/M) and 
mean ±SD 6/6 and 3/7, and 61 ± 8 and 60 ± 7yrs, respectively). Exclusion criteria 
appear in Supplemental Material 
 
The Cambridgeshire Research Ethics Committee and the UK Administration 
of Radioactive Substances Advisory Committee approved this study. Written 
informed consent to participate was obtained from all subjects.  
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As part of standard clinical care, non-contrast CT (NCCT) and CTp were 
acquired in immediate succession during the hyper-acute phase, in the same 
orientation. See Supplemental Material for scanning procedures. 
 
PET 
Patients underwent both PK and FMZ PET, respectively in the subacute (day 
13-28, counting stroke day as day 0) and early chronic (6-21 weeks) post-stroke stage. 
For PK this time window relied on previous clinical studies showing it to be optimal 
for post-stroke MA (Sette et al., 1993, Gerhard et al., 2005, Price et al., 2006). For 
FMZ it was chosen to allow post-stroke SNL to become established (Nakagawara et 
al., 1997, Guadagno et al., 2008). Note that SNL, once established, is stable (Sette et 
al., 1993, Nakagawara et al., 1997), whereas post-stroke MA is transient (Ramsay et 
al., 1992, Sette et al., 1993, Price et al., 2006) . 
Details on PET scanning procedures are provided in Supplemental Material.   
 
MRI 
Scans were performed immediately prior to or after each PET scanning 
session. Details on sequences used appear in Supplemental Material.  
 
Image processing and data analysis  
CT perfusion 
The procedures, including the identification of penumbral voxels, followed 
those previously published in detail by our group (Guadagno et al., 2008, Alawneh et 
al., 2011, Carrera et al., 2013), and are presented in Supplemental Material.  
 
Infarct map and PET-MR image co-registration 
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The final infarct was manually outlined on the FLAIR images (with help from 
inspection of corresponding T1 images whenever judged useful) by an experienced 
neurologist and imaging scientist (JCB) blinded to the clinical data (see Figure 1 for 
an illustration). PET-MR coregistration was carried out as detailed previously 
(Guadagno et al., 2008, Alawneh et al., 2011, Carrera et al., 2013). Further 
information is available in Supplemental Material.  
 
PET 
Binding potential (BPND) maps were generated voxel-wise for both FMZ and 
PK, using the basis function version of the simplified tissue reference model (STRM) 
(Lammertsma and Hume, 1996, Gunn et al., 1997) in Receptor Parametric Mapping 
(RPM) software, which controls for tracer entry in brain tissue. See Supplemental 
Material for further details.  
 
Mapping SNL and MA within the ultimately non-infarcted MCA territory 
Note that CTp data were not used for this analysis.  
FMZ: voxel-based single-subject analysis 
We aimed to map and count, in each patient relative to the group of normal 
controls, the voxels with significantly reduced FMZ BPND present within the affected-
side MCA territory but outside the final infarct, as well as within the mirror mask in 
the unaffected hemisphere. This was accomplished by applying a single-subject 
voxel-wise analysis, which followed the methodology originally published by 
Signorini et al (Signorini et al., 1999) and detailed in Guadagno et al (Guadagno et 
al., 2008) and in Supplemental Material.  
 
PK: voxel-based single-subject analysis 
The individual-subject SPM analysis implemented for FMZ was not applicable 
to the PK data because PK BPND values, expressed relative to the cerebellum, are 
close to zero in normal brain tissue, with negative as well as positive values. We 
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therefore applied the method previously used in Price et al (Price et al., 2006) and 
detailed in Supplemental Material.  
In order to increase sample size, two of the four patients previously reported 
by Price et al (Price et al., 2006), whose PK study was within the same time-window 
as the present study (pts 1 and 2 of their Table 1; PK studies carried out day 13 and 
day 25 post-stroke, respectively) were included in the present analysis. Apart from not 
undergoing a CTp on admission, and therefore being ineligible for the subsequent 
analyses regarding the NIP, these two patients were similar to the rest in terms of 
admission NIHSS and 24hrs recovery, see Table 2.  
 
Mapping SNL and MA within the non-infarcted penumbra (NIP) 
For this analysis, all three imaging modalities, namely PET, MR and acute-
stage CTp, were used in conjunction and co-registration. Image processing details are 
provided in Supplemental Material.  Given the ‘pixellated’ nature of the NIP mask 
and the required cross-modalities image co-registration to native PET space, the 
voxel-based analysis described above for the non-infarcted MCA masks was not 
applicable. Instead, the FMZ and PK BPND values across all voxels belonging in the 
NIP and mirror NIP masks were extracted in each subject, and compared across 
patients for statistical significance.  
 
Relationship between SNL and MA 
The relationship between SNL and MA was determined by correlation 
analyses, first within the non-infarcted MCA territory (both across the sample and 
individually), and then within the NIP proper across the sample. See Supplemental 
Material for details.  
 
Statistical analysis 
To test the hypothesis that SNL (or MA) is present in the non-infarcted MCA 
territory, we assessed across the sample whether the number of FMZ (or PK) BPND 
voxels within the non-infarcted MCA mask that survived the statistical threshold 
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determined in the healthy controls was significantly higher than the corresponding 
voxel number in the mirror mask, as described elsewhere (Price et al., 2006, 
Guadagno et al., 2008). To test this difference, non-parametric Wilcoxon signed-rank 
tests were used given the intrinsic zero-voxel floor effect (i.e., no surviving voxel) 
intrinsically skewing the distribution, and the wide distribution of actual voxel 
numbers exposing to the risk of outliers (see Table 3). Comparing the two 
hemispheres aimed to account for potential non-specific, bilaterally distributed 
changes in binding sites in the stroke population studied, either pre-morbid or 
secondary to stroke-related diffuse effects such as Wallerian degeneration (Gerhard et 
al., 2005, Guadagno et al., 2008). To investigate whether age, time from onset to PET 
data acquisition or final infarct volume influenced the results, non-parametric 
correlation between the inter-hemispheric difference in significant voxel numbers and 
these potential confounders were also assessed. 
 
 To test the hypothesis that significant SNL affects the NIP, we assessed 
whether, across patients, the individual mean FMZ BPND values within the NIP mask 
was significantly higher than that in the mirror mask, again using non-parametric 
Wilcoxon signed-rank tests given the small sample and the risk of outliers. The same 
procedure was repeated for PK BPND values. 
 
Two-tailed P <.05 was regarded as significant throughout. 
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Out of 29 eligible patients, 10 declined to volunteer for the study and 19 
consented. One patient subsequently withdrew consent, and PET studies failed in 
another two, leaving a total of 16 patients effectively included. In the same period, 
229 pts underwent CTp in our centre as potential candidates for thrombolysis, of 
which 152 had a final diagnosis of anterior circulation stroke.  
The main demographics and clinical data of the 16 included patients are 
presented in Table 1. There were 9 males and 7 females, median age was 66yrs and 
median admission NIHSS was 12 (range 3-21). Twelve patients were thrombolysed, 
and none thrombectomized. Table 2 shows the NIHSS scores at admission, 24hrs and 
time of the PET scans, as well as the stroke-to-PET delays and infarct volume. 
PET scanning 
Fifteen patients successfully underwent FMZ-PET, 14 PK-PET and 13 both 
scans (Table 2). Both scans were not performed in three patients because of failed PK 
synthesis within the prescribed time-window (n=2) and withdrawal from the study 
after FMZ-PET (n=1; this patient however agreed to let us use her PK dataset). 
SNL and MA in the non-infarcted MCA territory 
FMZ:  
Out of 15 patients, seven showed a greater number of voxels surviving the cut-
off in the affected than unaffected hemisphere - often markedly so -, two had mildly 
higher voxel number in the unaffected hemisphere, and six had no significant voxels 
in either hemisphere (Table 3). This distribution was statistically significant in favour 
of the affected hemisphere (Wilcoxon signed-rank test, z = -2.073, p = .039, r = 0.60; 
number of significant voxels: medianaffected =101 vs medianunaffected =0). Figure 2 
illustrates typical SPM findings across several brain slices in the same patient as 
shown in Figure 1, depicting the expected ‘patchy’ pattern of significant FMZ binding 
loss across the non-infarcted cortical MCA territory. See Supplemental Material for 
further results. 
PK: 
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The PK ratio was larger in the affected than unaffected hemisphere in 12/16 
patients (Table 3), and across patients significantly increased on the affected 
hemisphere compared to the unaffected (median= 2.2% vs 1.5%; p= 0.021, Wilcoxon 
signed-rank test). In addition, the (affected – unaffected) inter-hemispheric (A-U) PK 
ratio difference was significantly larger in patients as compared to the 10 controls 
(median = 5.5 and 0.08%, respectively; p=0.008, Mann-Whitney test). Individually, 
the (A-U) difference in PK ratio was beyond the upper 95% confidence limit for inter-
hemispheric difference derived from the the 10 controls in 11/16 patients (see Table 3 
for details).  
FMZ-PK relationship within the non-infarcted MCA mask (n=13) 
There was no significant correlation between interhemispheric (A-U) 
difference in number of FMZ and PK significant voxels (tau= -0.128, p= 0.56). In the 
within-subject analysis, the correlation between FMZ BPND A/U ratio and PK BPND 
(A-U) difference did not reach statistical significance in any patient. 
 
SNL and MA within the non-infarcted penumbra (NIP) 
Table 4 shows for each subject the mean FMZ and PK BPND values in the NIP 
and mirror NIP masks, the mean FMZ A/U ratio and the mean PK (A – U) difference. 
FMZ  
All 15 subjects who underwent an FMZ study had a lower mean FMZ BPND in 
the NIP compared to the mirror NIP, a statistically significant distribution (medianNIP 
= 2.76 and 3.15, respectively; Wilcoxon signed-rank test, z = -3.408, p = 0.001).  
PK 
Nine/14 patients had a higher mean PK BPND in the NIP compared to the 
mirror NIP (median = -0.0926 vs -0.115, respectively), however this difference did 
not reach statistical significance (Wilcoxon signed-rank test, z = 1.35, p = .177].  
Despite this negative finding across patients, visual inspection of the 
individual image datasets suggested the presence of increased PK binding within 
cortical NIP in three patients (# 2, 9 and 16). Figure 1 illustrates for a single axial 
plane from patient 2 the presence of increased PK binding in the cortical NIP (yellow 
Page 13 of 36





arrows), associated with reduced FMZ binding (red arrows). Accordingly, this patient 
had the highest (A-U) PK difference in the NIP (Table 4), along with the second 
lowest FMZ (A/U) ratio. The (A-U) PK difference in the other two patients was 
however unremarkable. Note that comparing these values to normative data was not 
feasible, as mimicking the NIP mask in the control subjects was deemed impossible, 
or far too inaccurate. 
Relationship between SNL and MA within the NIP 
Across the 13 patients, there was no significant relationship between mean 
FMZ BPND A/U ratio and mean PK BPND (A-U) difference within the NIP (Kendall’s 
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This prospective study is the first to assess, in the same subjects, both SNL and MA 
and their inter-relationships in the non-infarcted brain ipsilateral to MCA stroke. 
Consistent with but expanding from earlier reports, FMZ binding was significantly 
reduced and PK binding significantly increased in the whole non-infarcted MCA 
territory, for the first time documenting the co-occurrence of MA and SNL beyond the 
infarct. The focus of this study was however the salvaged penumbra per se. Consistent 
with our hypothesis, FMZ binding was highly significantly reduced, directly 
documenting the presence of SNL in the salvaged penumbra in man. Importantly, 
none of these novel findings could be ascribed to partial volume effects, given the 
stringent dilated infarct mask approach implemented. Finally, contrary to our 
hypothesis, only mild and non-significant increases in PK binding were found in the 
salvaged penumbra across the sample - although appeared to be present in one patient 
taken individually. Finally, there was no significant relationship between FMZ and 
PK binding changes either in the whole non-infarcted MCA territory or in the 
salvaged penumbra.     
 
Before addressing the mechanistic implications of these findings, some 
methodological points deserve comments. First, to identify the penumbra, we applied 
validated CTp thresholds (Wintermark et al., 2006, Murphy et al., 2008), as 
previously by us (Alawneh et al., 2011, Carrera et al., 2013). There is currently no 
consensus on which CTp thresholds to universally apply (Dani et al., 2011, Leigh et 
al., 2017), and to date numerous CTp thresholds based on different perfusion 
variables have been validated, though all in single or dual studies only (Wintermark et 
al., 2006, Murphy et al., 2008, Lin et al., 2014, McVerry et al., 2014, Copen et al., 
2015, Cereda et al., 2016, Mokin et al., 2017). Furthermore, in order to identify the 
penumbra, both penumbral and core perfusion thresholds must be applied, yet the 
latter is by definition time-dependent (Jones et al., 1981, Baron, 2001), as recently 
confirmed in stroke patients (d'Esterre et al., 2015, Bivard et al., 2017). Applying the 
same CTp thresholds as those used here previously yielded biologically meaningful 
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and expected results, particularly regarding clinical correlations (Alawneh et al., 
2011). Furthermore, tissue compartment volumes derived from the various validated 
thresholds are closely inter-related, and their relationships with clinical or tissue 
outcome appear stable across thresholds (Christensen et al., 2009, Bivard et al., 2011, 
Lin et al., 2016). Accordingly, changing the thresholds in sensitivity analyses in our 
previous study did not affect the overall results (Alawneh et al., 2011). As a matter of 
fact, the three main CTp variables not only derive from the same contrast agent 
concentration time-course, but are also mathematically inter-related (i.e., MTT = 
CBF/CBV), so that different thresholds capture widely overlapping voxel subsets. 
Second, only two CTp slabs were available, so any MA present in cranial- and caudal-
most axial sections would have been missed. Third, we used the specific PET ligands 
FMZ and PK to investigate SNL and MA, respectively. As FMZ binds selectively to 
the neuron-specific GABAa receptor, we were unable to investigate the white matter 
component of the salvaged penumbra, may have missed SNL affecting non-GABAa 
neuronal populations, and, due to locally low GABAa-receptor density, were unable 
to investigate striatal SNL, which is commonly seen after brief proximal MCAo in 
rodents (Fujioka et al., 2003, Katchanov et al., 2003, Baron et al., 2014, Brunner et 
al., 2017). As a result, we may have underestimated the extent/magnitude of SNL. 
Regarding PK, it almost exclusively reflects MA (Ejaz et al., 2016) so our findings 
essentially do not reflect other components of post-stroke inflammation such as 
astrocytosis and infiltration by blood-borne neutrophils and monocytes. Although PK 
and FMZ have been formally validated in rodent stroke models as in vivo markers of 
MA and SNL, respectively (see Introduction), direct validation of their intended 
pathological substrates in humans is available for 
3
H-labeled PK only (Benavides et 
al., 1988).  Fourth, although sizeable, our sample was relatively small. However i) our 
FMZ and PK samples taken separately were both larger than any previous similar 
study (see Introduction); ii) significant FMZ reductions and PK increases were clearly 
demonstrated despite the relatively small samples; and iii) no previous clinical stroke 
study has involved both FMZ and PK PET. More generally, assembling a sample of 
stroke patients with documented acute penumbra, marked early recovery and 
willingness to undergo two ligand PET studies represents a major achievement - not 
to mention successfully completing such complex investigations. However, our 
findings apply only to patients fulfilling these criteria, and may not generalize to the 
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entire stroke population. That said, our sample does reflect current candidates for 
thrombolysis and bridging therapy. 
Although well-established in rodent models (see (Baron et al., 2014) for 
review), this study is the first to formally document the existence of SNL in the 
surviving penumbra in man. The only previous similar study that used FMZ in 
conjunction with acute perfusion imaging documented SNL in the non-infarcted MCA 
territory but did not directly assess the NIP (Guadagno et al., 2008). Another small-
scale FMZ-PET study (Carrera et al., 2013) provided only indirect support to the 
presence of SNL in the NIP. Two SPECT studies suggested the presence of SNL in 
the NIP (Nakagawara et al., 1997, Saur et al., 2006) but had significant 
methodological limitations (see Introduction for details).  
In our previous study (Guadagno et al., 2008) the hypothesis that SNL affects 
the NIP was indirectly tested by assessing the relationship between FMZ binding and 
acute-stage perfusion across ROIs sampling the affected hemisphere, which revealed 
the predicted significant negative relationship. Here, in contrast, it was feasible to co-
register the PET, MRI and acute-stage CTp datasets, which allowed us to directly 
document reduced FMZ in the NIP. In a post-hoc analysis applying the Guadagno et 
al’s methodology onto the present material, no significant relationship between FMZ 
and perfusion was found either within- or across subjects (data not shown). This 
negative finding may be explained firstly because the present sample had less 
extensive acute hypoperfusion than in Guadagno et al, reducing the chance of finding 
a relationship, and secondly because in the latter study the correlations, when 
significant, had very shallow slopes. Applying the same methodology to the PK 
dataset, a significant positive PK-perfusion correlation (i.e., in the expected direction) 
was present in 3/13 patients, but a negative slope was found in 5 patients and the 
mean slope did not differ from zero. This negative finding is consistent with the lack 
of significant MA in the NIP, while the presence of MA in the whole non-infarcted 
MCA mask likely reflects secondary degeneration (see below), whose link with acute 
hypoperfusion would not be expected.    
That the salvaged penumbra can be affected by SNL has potential clinical 
implications. First, although undetectable on standard MRI (yet possibly identifiable 
on very-high-field scanners), SNL may contribute to post-stroke neurological 
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impairment over and above that resulting from the infarct per se. Second, SNL may 
also affect the potential for reorganization and plasticity in the salvaged penumbra, 
and in turn hinder recovery. Although in rats isolated SNL is associated with 
sometimes prolonged behavioral impairment (Sicard et al., 2006, Balkaya et al., 2013, 
Ejaz et al., 2015), only indirect evidence for such an effect exists in man (see 
Introduction). To test whether SNL impacted recovery (i.e., FMZ-study minus 
admission NIHSS) in the present study, we added SNL severity to our previously 
validated linear model including salvaged penumbra and extra-penumbral infarct 
extension (Alawneh et al., 2011, Tisserand et al., 2014), which however failed 
because 11/16 patients had 100% recovery (see Table 2). Using non-parametric partial 
correlations to at least partly account for this ceiling effect, salvaged penumbra 
volume had the expected positive effect on NIHSS recovery, but not SNL (data not 
shown). However, this ceiling effect prevented the proper testing of this hypothesis. 
Given the NIHSS only includes major neurological impairments, simple validated 
assessments of manual dexterity (Calautti et al., 2007) and left- and right-sided MCA 
stroke-related cognitive deficits (Hillis et al., 2002) were prospectively part of this 
study’s protocol. However, it proved practically impossible to administer them in the 
hyperacute stroke setting, and eventually this data was available in too few patients 
for meaningful analysis. These issues notwithstanding, preventing SNL as an adjunct 
to reperfusion therapies might facilitate and even perhaps enhance ultimate post-
stroke recovery. 
Our second main hypothesis was that the NIP would also be affected by MA in 
man. Contrary to this hypothesis, however, our data for the NIP showed only mild and 
non-significant PK BPND increases. Rather than a sample size issue, this negative 
finding might reflect the stringent dilated infarct mask methodology implemented, 
which, as per our previous study (Price et al., 2006), was necessary because PVEs 
may cause spill-out of the high PK binding present in necrotic tissue - reflecting 
massive macrophage-led phagocytosis - onto neighbouring cortex (see Figure 1). Note 
however that there is currently no alternative to PET to assess MA in vivo. Although 
we cannot formally exclude the presence of MA in the immediate peri-infarct rim, this 
is a small region that in addition includes the peri-infarct inflammatory scar 
(Moskowitz et al., 2010), which has no clear clinical relevance. In addition, despite 
using the same methodology, we did detect the presence of SNL in the NIP, as 
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predicted, with high statistical significance. Our hypothesis was based on consistent 
observations in rodents of marked MA in the salvaged penumbra, as biologically 
expected in close topographical congruence with SNL (Katchanov et al., 2003, 
Hughes et al., 2010, Ejaz et al., 2013, Ejaz et al., 2015). Given this topographical 
congruence and the fact that previous clinical FMZ-PET studies have shown cortical 
SNL to adopt a widely distributed patchy pattern (Guadagno et al., 2008, Carrera et 
al., 2013), as also found here (Figure 2), one might expect MA to be detectable just as 
easily as SNL was. Could our negative finding therefore relate to another feature of 
our study, namely the timing of PK-PET, 14-28 days post-stroke? Time-course studies 
in rodents have consistently shown prominent MA in the stroke hemisphere from day 
3 up to day 28, peaking around day 7-14, and only slightly declining by day 28 
(Benavides et al., 1990, Cremer et al., 1992, Fukumoto et al., 2010, Lartey et al., 
2014, Walberer et al., 2014, Martin et al., 2015). In baboons, PK binding in the peri-
infarct region showed a slightly slower time-course, peaking between days 20-30 
(Sette et al., 1993). Acknowledging the complexities involved in carrying out 
longitudinal PET studies in stroke patients, the available studies suggest a time-course 
similar to that in baboons (Ramsay et al., 1992, Gerhard et al., 2000, Price et al., 
2006). It is therefore unlikely that the peak of MA was missed in the present study. 
Taken together, therefore, our study provides strong evidence that MA is not present 
to any significant amounts in the NIP in man. Interestingly, however, visual 
inspection of the individual image datasets suggested it was perhaps present in three 
patients, and more conspicuously in one (see Figure 1). This suggests that although on 
average MA does not significantly affect the NIP in man, it may be occasionnally 
encountered. 
Consistent with this overall mismatch between SNL and MA in the NIP, there 
was not even a trend for a correlation between them in this tissue compartment 
(Figure 3). This negative finding conflicts with our rodent study revealing a 
significant correlation between SNL and MA, assessed post-mortem at day 14 post-
stroke (Hughes et al., 2010), reflecting the above-mentioned topographical 
congruence between these two processes. It is unlikely this discrepancy resulted from 
the exclusion of the immediate peri-infarct tissue here, since in man, like in rodents 
(Sicard et al., 2006, Hughes et al., 2010, Ejaz et al., 2013, Ejaz et al., 2015), cortical 
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SNL is patchy and widely distributed throughout the MCA territory (see above). A 
species difference may therefore exist.  
In turn our findings provide evidence that MA is unlikely to contribute to any 
significant degree to the SNL involving the NIP. Although MA is initially triggered 
by ischemic neuronal injury (Moskowitz et al., 2010), the mismatch and lack of 
correlation between these two processes found here suggest no lingering relationship 
between them in man. Our study’s clinical implication is therefore that interventions 
aimed at mitigating MA may not prevent penumbral SNL in man – or at the very least 
that trials testing this approach should screen for the occasional patients with imaging 
evidence of both MA and SNL affecting the NIP. Other mechanisms for SNL should 
therefore be considered. Prominent among them is ischemia-triggered neuronal 
damage (Guadagno et al., 2008), which if true could be prevented by improving 
penumbral perfusion or oxygenation until reperfusion is achieved (Shuaib et al., 2011, 
Ejaz et al., 2016, Poli et al., 2017, Savitz et al., 2017). Another potential mechanism 
for scattered cortical neuronal death is capillary obstruction - so-called no-reflow –, 
seemingly caused by pericyte contraction in severely ischemic areas(Yemisci et al., 
2009, Dalkara and Arsava, 2012).  
Using optimized methodology, the present study confirmed the presence of 
MA in the non-infarcted MCA territory, previously suggested by two small-scale 
studies (Gerhard et al., 2005, Price et al., 2006) (see details in Introduction). 
Furthermore, the lack of significant correlation between FMZ and PK changes in this 
tissue compartment despite significant changes in both ligands being present suggests 
topographical non-congruence, with SNL affecting cortical patches and MA being 
more distributed. As also detailed in Introduction, several clinical studies previously 
documented MA as a marker of remote degeneration after stroke (Pappata et al., 
2000, Gerhard et al., 2005, Radlinska et al., 2009, Thiel et al., 2010). It is likely the 
presence of MA in the whole non-infarcted MCA territory here reflects similar 
processes. Whether such remote degeneration is clinically relevant or represents an 
epiphenomenon is unclear. Some rodent studies suggest that blocking remote 
inflammation may reduce secondary damage in connected thalamic or brainstem 
nuclei (see for review (Zhang et al., 2012), with potential behavioural benefits, but 
others conversely suggest that post-stroke MA has pro-repair effects and that its 
pharmacological blockade may worsen behavioural outcome (Lalancette-Hebert et al., 
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2007, Moskowitz et al., 2010, Szalay et al., 2016, Jin et al., 2017). Although this 
dichotomy and time-course are hotly debated (Ransohoff, 2016), neurotoxic effects 
may predominate in the first week and pro-repair effects later on (Hu et al., 2012).  
 
Conclusion 
The present mechanistic dual-tracer PET study in a sizeable sample of MCA 
territory stroke patients establishes the presence of microglial activation in the non-
infarcted MCA territory taken as a whole, uncorrelated with neuronal loss. More 
important, we demonstrate for the first time the presence of patchy SNL affecting the 
MR normal-appearing cortical ribbon within the surviving penumbra. The lack of 
associated microglial activation suggests the latter may not contribute to SNL in 
human stroke. In turn, the presence of MA in non-infarcted areas probably represents 
remote degenerative processes rather than potentially neurotoxic inflammation further 
damaging the penumbra. The main clinical implications from our findings are, first, 
that SNL affecting the salvaged penumbra may hinder neuronal plasticity and 
functional recovery, and as such may represent a novel therapeutic target as an 
adjunct to reperfusion therapies; and, second, that microglial activation may not stand 
as primary target for interventions aiming to prevent SNL. Other interventions, such 
as improving penumbral perfusion/oxygenation before reperfusion is achieved and/or 
preventing capillary obstruction, may more efficiently prevent SNL. For such trials, 
FMZ-PET may be of use to monitor treatment effects. 
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Figure 1  
Illustrative image dataset (patient 2). Overlaid on the one-month FLAIR image are 
shown the infarct ROI and 14-mm dilated infarct ROI (red and blue contours, 
respectively; note that the Infarct ROI includes the caudate head, which is visible on 
the FLAIR image). To the left are shown the co-registered non-contrast CT and CTp 
scans (MTT map) obtained on this patient’s admission. Red arrows on the MTT map 
point to acute-stage penumbral areas. On the right are shown the co-registered FMZ 
and PK BPND maps. Visual inspection indicates a clear reduction in FMZ BPND (red 
arrows) together with increased PK BPND (yellow arrows) within the non-infarcted 
penumbra (and outside the dilated infarct ROI). Note also the massive PK11195 
uptake within the infarcted area (blue arrowhead). Refer to Tables 3 and 4 for 
individual FMZ and PK BPND values in the non-infarcted MCA territory and non-
infarcted penumbra (NIP) in this patient. Consistent with these visual observations, 
this patient had the second lowest FMZ (A/U) ratio and highest (A-U) PK difference 
in the NIP.   
Figure 2 
Illustrative SPM readouts from Patient 2 (same patient as in Figure 1) showing, 
projected onto 5 axial cuts from a normal T1-MRI template for anatomical 
orientation, typical clusters of significant FMZ binding reduction (as compared to 12 
healthy controls, see Methods) scattered across the right MCA-territory cortical 
ribbon (yellow blobs), i.e., ipsilateral to the stroke, with only few similar clusters on 
the left cortical ribbon (blue blobs; see Methods for an explanation as to how and why 
such clusters were identified in the unaffected hemisphere). Quantitative FMZ data 
for this patient are shown in Table 3. 
Figure 3 
Scatterplot of the relationship between FMZ affected/unaffected (A/U) side ratio and 
PK (A-U) side difference for the non-infarcted penumbra (see Methods). This plot 
shows no clear relationship between the two variables, which was confirmed by the 
statistical analysis (Kendall’s tau = -0.154, p = 0.464). Note that Kendall’s rank 
correlation corrects for any potential outlier. Note also the data point at the bottom 
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right corner of the sample, ie, with highest PK value and the second lowest FMZ 
value in the NIP, corresponds to Patient 2, in whom visual inspection of the image 
dataset suggested the presence of increased PK binding in the NIP (see Figure 1).  
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1  F 61 L     Y 3 
2 F 74 R     Y 5 
3 M 54 R     Y 2 
4 M 49 L     Y 3 
5 F 74 L     Y 3 
6 F 80 R     Y 3 
7 M 56 L     Y 3 
8 M 55 L     Y 3 
9 F 71 R     Y 3 
10 M 64 R     Y 2 
11 M 59 R     Y 3 
12 M 87 L     N 3 
13 M 68 L     N 3 
   14 M 53 R     Y 5 
15 M 74 R     N 2 
16 F 76 L     Y 5 
 
L: left; R: right; HTN : hypertension, DM : diabetes mellitus;  present  absent ; §TOAST criteria 1: 
Severe carotid stenosis, 2: Large artery disease, 3: Cardioembolic cause, 4: Other determined cause, 5: 
Undetermined 
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Table 2. PET data acquisition delays, NIHSS data and infarct volume for the 16 patients recruited 
into the present study (#1-16) and the two additional PK patients from Price et al, 2006. 
CT: computerized tomography; *interval calculated from when last seen well; &: total infarct 
volume across the whole brain, obtained at FMZ session whenever applicable, otherwise at 
PK session (see Methods); a: these two patients were initially reported in Price et al (Price et 
al., 2006), see Methods for details; n/a – not available/not applicable. 
Patient 
Stroke 



















1  109 4 2 24 1 43 1 11.0 
2 91 18 10 18 10 50 10 14.1 
3 89 20 3 17 2 100 2 98.5 
4 191 4 0 21 0 146 0 2.0 
5 148 21 3 16 3 147 3 11.5 
6 131 19 0 13 0 48 0 31.3 
7 140 3 0 27 0 119 0 0.3 
8 94 5 0 15 0 47 0 1.3 
9 147 15 0 21 0 58 0 0.7 
10 142 11 0 22 0 84 0 5.1 
11 83 7 2 16 0 92 0 0.2 
12 312* 13 1 26 1 104 1 3.0 
13 142 5 1 26 1 89 0 5.2 
14 234 2 0 n/a n/a 41 0 6.0 
15 145 6 1 n/a n/a 116 0 54.6 
16 118 8 1 13 1 n/a n/a 7.0 
 17
a
 n/a 19 10 13 n/a n/a n/a 25.3 
 18
a
 n/a 13 1 25 n/a n/a n/a 2.7 
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Table 3.  Number of statistically significant FMZ voxels in the non-infarcted MCA and 
mirror masks, corresponding PK ratios, and (affected minus unaffected) (A – U) difference in 
these variables, for each of the 16 patients included in the present study plus the two PK 









FMZ   
(A – U)  








(A – U) 
Difference 
(%)                
1  480 200 280 1.13 0.38  0.75* 
2 2393 1286 1107 3.00 2.24  0.74* 
3 0 111 -111 9.05 7.67  1.38* 
4 0 0 0 2.31 1.58  0.73* 
5 101 0 101 2.04 3.38       -1.34 
6 0 0 0 0.52 0.64       -0.12 
7 0 0 0 4.32 3.90   0.42* 
8 368 0 368 6.62 7.19 -0.57 
9 303 532 -229 2.01 1.51    0.50* 
10 0 0 0 0.30 0.36 -0.06 
11 0 0 0 0.89 0.75  0.14 
12 4768 2296 2472 0.80 0.36    0.44* 
13 0 0 0 2.39 1.67    0.72* 
14 895 0 895 n/a n/a n/a 
15 345 0 345 n/a n/a n/a 
         16           n/a         n/a n/a          2.46   1.17   1.29* 
         17           n/a         n/a       n/a          4.45 2.86   1.59* 
        18           n/a         n/a      n/a          1.01 0.42   0.59* 
*: value higher than the upper 95% confidence limit for the inter-hemispheric difference in PK ratio 
derived from the 10 control subjects who underwent a PK PET study (value: 0.35%). 
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Table 4. Mean FMZ and PK BPND values within the non-infarcted penumbra and mirror 
masks, and their corresponding A/U ratio and (A-U) difference, respectively, in the 16 
patients recruited in the present study. Also shown is the volume of non-infarcted penumbra, 
assessed in two CT perfusion slices. See Methods for details and Results for statistical 
findings. 
 

















1  2.030 2.032 0.999 -0.097 -0.116 0.019 92.3 
2 2.764 3.377 0.818 -0.032 -0.137 0.105 62.1 
3 2.647 3.023 0.876 -0.024 -0.070 0.046 53.3 
4 2.188 2.359 0.927 -0.063 -0.089 0.026 24.1 
5 3.119 3.555 0.878 -0.053 -0.028 -0.024 26.3 
6 2.782 3.153 0.883 -0.088 -0.086 -0.002 46.6 
7 2.304 2.801 0.823 -0.151 -0.126 -0.025 34.6 
8 2.165 2.325 0.931 -0.112 -0.115 0.004 31.1 
9 2.221 2.339 0.950 -0.060 -0.053 -0.007 71.2 
10 2.495 2.582 0.966 -0.134 -0.118 -0.016 40.1 
11 3.100 3.253 0.953 -0.128 -0.138 0.011 75.9 
12 2.900 3.623 0.800 -0.037 -0.102 0.065 24.0 
13 2.880 3.485 0.827 -0.143 -0.144 0.001 56.6 
14 4.182 4.540 0.921     n/a      n/a n/a 96.6 
15 3.369 4.023 0.838    n/a     n/a n/a 24.6 
16     n/a         n/a n/a -0.099 -0.117 0.018 48.9 
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Acute NCCT Acute CTp 11C-PK11195 
11C-Flumazenil 1-month FLAIR 
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